Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$44.18 ▲ +0.93
(+2.15%)
MKT CAP: $5.38B • VOL: 1.29M
52W L $27 52W H $62
SRRK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $0 | $0 | $0 |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$384.6M | -$252.1M | -$171.3M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$378.0M | -$246.0M | -$166.0M |
| EBITDA (Normalized) | -$384.2M | -$252.0M | -$171.3M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$300.0M | -$200.9M | -$145.2M |
| Capital Expenditures (CapEx) | $602.0K | $98.0K | $0 |
| Free Cash Flow (FCF) | -$300.6M | -$201.0M | -$145.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -7.6% |
| Cash & Short-Term Equivalents | $323.5M | $177.9M | $325.5M |
| Total Debt (Short + Long Term) | $99.7M | $50.1M | $692.5M |
| Total Stockholders' Equity | $245.5M | $368.6M | $1.42B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SRRK.